Toboroz
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yan Ji (principal investigator)
Toboroz
Family Communications After Genetic Testing
NCT07143487· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yan Ji (principal investigator)
Toboroz
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Forrás
Contact: Margaret B. Nolan (principal investigator)
Toboroz
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
NCT07018869· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Margaret B. Nolan (principal investigator)
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· 3. fázis· NRG Oncology· Forrás
Contact: Charles Shideman (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Yan Ji (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yan Ji (principal investigator)
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Contact: Jessica A. Thomes Pepin (principal investigator)
Toboroz
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Forrás
Contact: Bret EB Friday (principal investigator)
Toboroz
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: David M. King (principal investigator)
Fut, nem toboroz
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: David M. King (principal investigator)
Toboroz
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: David M. King (principal investigator)
Fut, nem toboroz
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038· PrECOG, LLC.· Forrás
Fut, nem toboroz
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: David M. King (principal investigator)
Toboroz
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Margaret B. Nolan (principal investigator)
Toboroz
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT06073431· University of Rochester· Forrás
Contact: Sarah E. Jax (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Joleen M. Hubbard (principal investigator)
Fut, nem toboroz
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: David M. King (principal investigator)
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: David M. King (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yan Ji (principal investigator)
Toboroz
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yan Ji (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: David M. King (principal investigator)
Fut, nem toboroz
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
NCT05241860· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yan Ji (principal investigator)
Fut, nem toboroz
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Joleen M. Hubbard (principal investigator)
Toboroz
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
NCT05058651· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: David M. King (principal investigator)
Fut, nem toboroz
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: David M. King (principal investigator)
Fut, nem toboroz
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· 3. fázis· NRG Oncology· Forrás
Toboroz
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Forrás
Contact: Yan Ji (principal investigator)
Fut, nem toboroz
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
NCT04751370· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
NCT04829539· 3. fázis· University of Rochester NCORP Research Base· Forrás
Fut, nem toboroz
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· 2. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
NCT04394858· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: David M. King (principal investigator)
Toboroz
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: David M. King (principal investigator)
Fut, nem toboroz
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
NCT04548752· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04315324· 1/2. fázis· SWOG Cancer Research Network· Forrás
Toboroz
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: David M. King (principal investigator)
Toboroz
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: David M. King (principal investigator)
Showing 50 of 116.